Cost-Effectiveness of Umeclidinium/Vilanterol versus Salmeterol/Fluticasone in Elderly Patients with Chronic Obstructive Pulmonary Diseases in China

References

• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; 2020 [ Updated 2021]. Available from: https://goldcopd.org/2021-gold-reports/. Accessed October 21, 2021.
   Google Scholar
• Yin P, Wang H, Vos T, et al. A subnational analysis for mortality and prevalence of chronic obstructive pulmonary disease in China 1990–2013: findings from Global Burden of Disease Study. Chest. 2016;150(6):1269–1280. doi:10.1016/j.chest.2016.08.1474
   PubMed Web of Science ®Google Scholar
• Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet. 2018;391(10131):1706–1717. doi:10.1016/S0140-6736(18)30841-9
   PubMed Web of Science ®Google Scholar
• Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2019;394(10204):1145–1158. doi:10.1016/S0140-6736(19)30427-1
   PubMed Web of Science ®Google Scholar
• Zhu B, Wang Y, Ming J, et al. Disease burden of COPD in China: a systematic review. Int J Chron Obstruct Pulmon Dis. 2018;13:1353–1364. doi:10.2147/COPD.S161555
   PubMed Web of Science ®Google Scholar
• Chen Z, Li WY, Ni XF, et al. Research and development status Quo of respiratory inhalation preparations: a systematic review. China Pharm. 2021;32(14):1671–1677. Chinese. doi:10.6039/j.issn.1001-0408
   Google Scholar
• Chronic Obstructive Pulmonary Disease Group, Respiratory Diseases Branch of Chinese Medical Association Chronic Obstructive Pulmonary Disease Working Committee of the Respiratory Physician Branch of the Chinese Medical Doctor Association. Guidelines for the diagnosis and treatment of chronic obstructive pulmonary disease (revised edition in 2021). Chin J Tuberc Respir Dis. 2021;44(3):170–204. Chinese. doi:10.3760/cma.j.cn112147-20210109-00031
   Google Scholar
• Horita N, Goto A, Shibata Y, et al. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2017;2(2):CD012066. doi:10.1002/14651858.CD012066.pub2
   PubMed Web of Science ®Google Scholar
• Wilson MR, Patel JG, Coleman A, et al. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model. Int J Chron Obstruct Pulmon Dis. 2017;12:997–1008. doi:10.2147/COPD.S124420
   PubMed Web of Science ®Google Scholar
• Rajagopalan K, Bloudek L, Marvel J, et al. Cost-effectiveness of twice-daily indacaterol/ glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US. Int J Chron Obstruct Pulmon Dis. 2018;13:3867–3877. doi:10.2147/COPD.S177097
   PubMed Web of Science ®Google Scholar
• Liu GG, Hu SL, Wu JH, et al. China Guidelines for Pharmacoeconomic Evaluations. 2020th ed. Beijing: China Market Press; 2020.
   Google Scholar
• Fang L, Gao P, Bao H, et al. Chronic obstructive pulmonary disease in China: a nationwide prevalence study. Lancet Respir Med. 2018;6(6):421–430. doi:10.1016/S2213-2600(18)30103-6
   PubMed Web of Science ®Google Scholar
• Spencer M, Briggs AH, Grossman RF, et al. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics. 2005;23(6):619–637. doi:10.2165/00019053-200523060-00008
   PubMed Web of Science ®Google Scholar
• Earnshaw SR, Wilson MR, Dalal AA, et al. Cost-effectiveness of fluticasone propionate/salmeterol (500/50 mg) in the treatment of COPD. Respir Med. 2009;103(1):12–21. doi:10.1016/j.rmed.2008.10.005
   PubMed Web of Science ®Google Scholar
• Chen R, Gao Y, Wang H, et al. Association between adherence to maintenance medication in patients with COPD and acute exacerbation occurrence and cost in China: a retrospective cohort database study. Int J Chron Obstruct Pulmon Dis. 2020;15:963–971. doi:10.2147/COPD.S234349
   PubMed Web of Science ®Google Scholar
• Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–789. doi:10.1056/NEJMoa063070
   PubMed Web of Science ®Google Scholar
• Maqsood U, Ho TN, Palmer K, et al. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2019;2(2):CD012930. doi:10.1002/14651858.CD012930.pub2
   Web of Science ®Google Scholar
• Wise RA, Anzueto A, Cotton D, et al. Investigators, Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med. 2013;369(16):1491–1501. doi:10.1056/NEJMoa1303342
   PubMed Web of Science ®Google Scholar
• Selya-Hammer C, Gonzalez-Rojas GN, Baldwin M, et al. Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat fixed-dose combination for chronic obstructive pulmonary disease patients in Italy. Ther Adv Respir Dis. 2016;10(5):391–401. doi:10.1177/1753465816657272
   PubMed Web of Science ®Google Scholar
• Wu M, Zhao Q, Chen Y, et al. Quality of life and its association with direct medical costs for COPD in urban China. Health Qual Life Outcomes. 2015;13(1):57. doi:10.1186/s12955-015-0241-5
   PubMed Web of Science ®Google Scholar
• Rutten-van Mölken MP, Hoogendoorn M, Lamers LM. Holistic preferences for 1-year health profiles describing fluctuations in health: the case of chronic obstructive pulmonary disease. Pharmacoeconomics. 2009;27(6):465–477. doi:10.2165/00019053-200927060-00003
   PubMed Web of Science ®Google Scholar
• Fang CS. The cost effectiveness analysis of indacaterol versus tiotropium in Chinese medical cost setting. Drug Eval. 2016;13(1):34–39. doi:10.3969/j.issn.1672-2809.2016.01.008
   Google Scholar
• Chen X, Wang N, Chen Y, et al. Costs of chronic obstructive pulmonary disease in urban areas of China: a cross-sectional study in four cities. Int J Chron Obstruct Pulmon Dis. 2016;11:2625–2632. doi:10.2147/COPD.S118523
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Neffen H. A systematic review on the efficacy and safety of a fixed-dose combination of umeclidinium and vilanterol for the treatment of COPD. Chest. 2015;148(2):397–407. doi:10.1378/chest.15-0084
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Comparative effectiveness and safety of LABA-LAMA vs LABA-ICS treatment of COPD in real-world clinical practice. Chest. 2019;155(6):1158–1165. doi:10.1016/j.chest.2019.03.005
   PubMed Web of Science ®Google Scholar